Check for updates

OPEN ACCESS

EDITED BY Sumant Inamdar, University of Arkansas System, United States

REVIEWED BY Ma Xiaobin, Second Affiliated Hospital of Xi'an Jiaotong University, China Qingfeng Hu, Fudan University, China

*CORRESPONDENCE Qiang Zhao 2238982818@qq.com

SPECIALTY SECTION

This article was submitted to Gastroenterology and Cancer, a section of the journal Frontiers in Gastroenterology

RECEIVED 31 May 2022 ACCEPTED 20 September 2022 PUBLISHED 24 October 2022

CITATION

Li H, Zhao Q, Si S and Wu D (2022) An association study on PSCA rs2294008 polymorphism and gastric cancer: A meta-analysis. *Front. Gastroenterol.* 1:944525. doi: 10.3389/fgstr.2022.944525

COPYRIGHT

© 2022 Li, Zhao, Si and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

An association study on PSCA rs2294008 polymorphism and gastric cancer: A meta-analysis

HangLong Li¹, Qiang Zhao^{2*}, ShuHan Si¹ and DongKai Wu¹

¹Changzhi Medical College, Changzhi City, Shanxi Province, China, ²Heping Hospital Affiliated to Changzhi Medical College, Changzhi City, Shanxi Province, China

Studies have confirmed that prostate stem cell antigen (PSCA) rs2294008 C>T polymorphism is related to gastric cancer susceptibility, but some studies have reached the opposite conclusion. In this meta-analysis, we attempted to clear up these differences and explore the relationship between the different factors that influence susceptibility to gastric cancer. Studies with publication dates that preceded 16 April 2022 were selected from PubMed, Springer, EMBASE, and Web of Science, and the relationship between risk models and gastric cancer was analyzed by odds ratios (ORs) and 95% confidence intervals. Consequently, it was confirmed that PSCA rs2294008 polymorphism leads to an increased risk of gastric cancer. Subgroup analysis found that individuals with diffuse gastric cancer, non-cardia gastric cancer, Helicobacter pylori (HP)positive or who are from the white or Asian population faced an increased susceptibility to gastric cancer. Those from the white populations faced significantly higher risks than Asians, and the association of PSCA with gastric cancer could be significantly increased by genome-wide association analysis. However, the conclusion that smoking reduces susceptibility to gastric cancer appears to be abnormal. Further prospective investigations that involve smoking and have a larger sample size are required.

KEYWORDS

gene, polymorphism, PSCA, rs2294008, meta-analysis

Introduction

Gastric cancer (GC) has been widely studied for decades due to its extremely high morbidity and mortality rates. According to statistics, in 2020, around 1 million individuals have been diagnosed with gastric cancer and approximately 769,000 people have died of this disease, accounting for 7% of global deaths (1). The diversity of gastric cancer genes is a pivotal factor that hinders the precise treatment of GC. Among them, single nucleotide polymorphism (SNP) is an important cause of gene diversity, and

several studies show that SNPs can be used as predictive biomarkers of human genetic variation to detect individual cancer risk.

Prostate stem cell antigen (PSCA) is a protein derived from normal epithelial tissues of the bladder, kidney, esophagus, and stomach (2). SNPs in PSCA are associated with various tumors such as rs1045531 that increases the risk of prostate cancer in Chinese men (2), rs2294008 that increases susceptibility to gastric and bladder cancers (3), and while rs2294008 alters the progesterone receptor status, together with rs2976392, it increases the risk of breast cancer (4). Differences in SNPs can affect the biological behavior of tumors. Therefore, the study of SNPs will help to elucidate the function of PSCA, the low expression of which has been confirmed to be significantly associated with poor overall survival rates in gastric cancer (5). Among the SNPs in PSCA, rs2294008 and rs2976392 have been shown to significantly increase susceptibility to gastric cancer (6). Given that rs2976392 only increases cancer risk in Asian populations, rs2294008 may be more reasonable as a potential universal gastric cancer biomarker.

Several recent meta-analyses of PSCA rs2294008 C>T and GC susceptibility have confirmed the association. However, some of the most recent studies have suggested some different points. Sung et al. (7) found that PSCA has a carcinogenic effect on gastric cancer, but Alikhani et al. (8) never found a correlation between PSCA rs2294008 and gastric cancer. In addition, SNPs are closely related to gender, ethnicity, habits, etc. It has been reported that the prevalence of GC in men was twice that in women in the last century, but this ratio is now being inverted (9). Cai et al. (10) found a synergy between Helicobacter pylori (HP) and PSCA, but this information had not been analyzed before. Thus, we conducted this meta-analysis and compared how gender, HP infection, smoker status, and the genotyping methods discussed contribute to or indicate susceptibility to gastric cancer to improve the study of the correlation between PSCA rs2294008 C>T and gastric cancer.

Materials and methods

Search strategy

Studies on PSCA rs2294008 C>T polymorphisms were found using PubMed, Springer, EMBASE, and Web of Science and examined to determine the association with gastric cancer risk. Literature on the subject published before 16 April 2022 was included. The search was completed using these keywords: "PSCA" or "prostate stem cell antigen", "polymorphism" or "SNP" or "gene" and "gastric cancer" or "stomach cancer" or "GC". Eligible literature was retrieved from all of the publications. Furthermore, we hand-collected additional literature from the reference lists of review articles examined to ensure all potential eligible publications are included.

Inclusion criteria

The studies were included according to these rules: (1) the research mentions the correlation between PSCA rs2294008 C>T polymorphism and the risk of GC. (2) It meets the requirements of a case-control study. (3) The study provides odds ratios (ORs) and 95% confidence intervals (CIs).; (4) Published literature provides detailed genotype distribution data. (5) The study subjects were gastric cancer patients and healthy people (precancerous lesions and other types of diseases were excluded).

Data extraction and summary

Data were screened by two fellows, and if any disagreement was unresolved, it was referred to a third researcher. For the record, the following information was extracted from all analyzed data: first author, year, country, ethnicity, control origin (population or hospital), genotyping method [e.g., Taqman, PCR-restriction fragment length polymorphism (RFLP), and Genome-Wide Association Studies (GWAS)], case and control sample quantities, distribution frequency of each genotype, Lauren classification (intestinal and diffuse), anatomical site (cardia and non-cardia), gender, HP infection, smoker status, and Hardy–Weinberg equilibrium (HWE) test results.

System analysis

Genetic models were formed according to genotype, and the ORs and 95% CIs of each model were determined to evaluate the relationship between PSCA rs2294008 C>T polymorphism and gastric cancer risk. They were then divided according to genotype distribution: the dominant model (CT+TT vs. CC), the recessive model (TT vs. CT+CC), homozygous (TT vs. CC), heterozygous (CT vs. CC), and the allelic (T vs. C). The goodness-of-fit chi-square test was used to test the deviation of the control group from the HWE, with a significant imbalance at the 0.05 level. A chi-square-based Q test was used to estimate heterogeneity in the different studies and the 12 statistic to quantify it. In cases where P<0.05 indicates significant heterogeneity between studies, the random-effects model was conducted. In other cases, a fixed-effect model was employed. The sensitivity analysis excluded each study once, and the summary ORs with 95% CIs were recalculated to determine how stable the summary data were. Begg's and Egger's tests were used to determine publication bias. Every statistic was performed using the Stata 15.0 software.

Results

Research characteristics

This meta-analysis included 28 eligible literature articles and 18,495 patients and 19,219 healthy controls (7, 8, 10-33).

Specific information on the included literature is shown in Table 1. Except for five articles, the control genotypes of all related studies had *P*-values higher than 0.05 in Hardy–Weinberg equilibrium (HWE), which is consistent with the genetic equilibrium in Mendelian populations. Figure 1 shows the process of searching for and selecting literature.

Among these studies, there are seven on white populations, 21 on Asians, and one on the Latin-American population. These populations were studied using the Taqman, Polymerase Chain Reaction-restriction fragment length polymorphism, Genome-Wide Association Studies, MassARRAY, and six other methods for genotyping. To differentiate control sources, they were further grouped into population-based (population-based controls) and hospitalbased (hospital-based controls), totaling 10 PBs and 19 HBs. In addition, we used Lauren classification, anatomical location, gender, HP infection, and smoker status as subgroups to study their effects on PSCA rs2294008 C>T polymorphism, including 12 anatomical subgroups with clear genotyping—six per gender and smoker status, and then four per Lauren classification and HP infection subgroup were used.

Quantitative synthesis results

By pooling all of the data together (Table 2), the polymorphism of PSCA rs2294008 C>T was associated with

TABLE 1 Study characteristics included in the meta-analysis.

CountryEthnictySOCGenotypingCaseCountryCCCTCCLochhead et al. (2011) (11)USAWhitePBTaqman308208851299494Lochhead et al. (2011) (11)PolandWhitePBTaqman20238247143102101Sala et al. (2012) (12)EuropeWhitePBTaqman1781,515931869494Rizzato et al. (2014) (14)GermanyWhitePBTaqman1381,5159316610264Sun et al. (2014) (15)GermanyWhitePBTaqman13012517644930Garcia-Gonzalez et al. (2015) (34)SpainWhiteHBTaqman60367515432182172Gonzales-Hormazable et al. (2002) (16)ChileOtherHBOther307310110162351124Frestudy Group of Millennium Genome Project for Cancer et al. (2008) (17)SpainAsianHBFaqman788783739138132160Wu et al. (2009) (18)ChinaAsianPBPCR-RFLP1,71099575981132506Matso et al. (2009) (19)JapanAsianPBPCR-RFLP1,603306537143132151Uu et al. (2010) (20)ChinaAsianPBPCR-RFLP1,6133,60547404 <td< th=""><th>110 4 166 11</th><th>FT HWE 49 0.405 115 <0.05</th></td<>	110 4 166 11	FT HWE 49 0.405 115 <0.05
Lochhead et al. (2011) (11)PolandWhitePBTaqman29238247143102101Sala et al. (2012) (12)EuropeWhitePBTaqman4091,51593198118491Rizzato et al. (2013) (13)GermanyWhitePBTaqman1781,057238669231Kupcinskas et al. (2014) (14)LithuaniaWhiteHBTaqman2512433311610264Sun et al. (2015) (34)USAWhiteHBTaqman13012517644930Gonzales-Hormazabal et al. (2020) (16)ChileOtherHBTaqman603675154302147199Gonzales-Hormazabal et al. (2008) (17)ChileOtherHBTaqman871390133461277122The Study Group of Millennium Genome Project for Cancer et al. (2008) (17)JapanAsianHBTaqman708759819132506Matsuo et al. (2009) (18)ChinaAsianHBTaqman70870833032949273Ou et al. (2010) (20)ChinaAsianHBPCR-RFLP1,0231,0695474072606Lu et al. (2011) (22)ChinaAsianHBPCR-RFLP4605492022164228	166 11	
Sala et al. (2012) (12)EuropeWhitePBTaqman4091,51593198118491Rizzato et al. (2013) (13)GermanyWhitePBTaqman1781,057238669231Kupcinskas et al. (2014) (14)LithuaniaWhiteHBTaqman2512433311610264Sun et al. (2014) (15)USAWhiteHBTaqman13012517644930Garcia-Gonzalez et al. (2015) (34)SpainWhiteHBTaqman603675154302147199Gonzales-Hormazabal et al. (2020) (16)ChileOtherHBOther3073101101623587The Study Group of Millennium Genome Project for Cancer et al. (2008) (17)KoreaAsianHBFQR-RFLP1,710995759819132506Matsuo et al. (2009) (18)ChinaAsianPBPCR-RFLP1,0231,06954740472673Ou et al. (2010) (20)ChinaAsianPBPCR-RFLP1,0231,06954740472605Lu et al. (2011) (22)ChinaAsianPBPCR-RFLP46054920221642545		15 <0.05
Rizzato et al. (2013) (13)GermanyWhitePBTaqman1781,057238669231Kupcinskas et al. (2014) (14)LithuaniaWhiteHBTaqman2512433311610264Sun et al. (2014) (15)USAWhiteHBTaqman13012517644930Garcia-Gonzalez et al. (2015) (34)SpainWhiteHBTaqman603675154302147199Gonzales-Hormazabal et al. (2020) (16)ChileOtherHBOther3073101101623587The Study Group of Millennium Genome Project for Cancer et al. (2008) (17)KoreaAsianHBTaqman871390133461277122Wu et al. (2009) (18)ChinaAsianPBPCR-RFLP1,710995759819132506Matsuo et al. (2010) (20)ChinaAsianHBTaqman70870833032949273Lu et al. (2010) (21)ChinaAsianPBPCR-RFLP1,0231,06954740472605Lu et al. (2011) (22)ChinaAsianHBPCR-RFLP4605492022164285	714 31	<0.05
Kupcinskas et al. (2014) (14) Lithuania White HB Taqman 251 243 33 116 102 64 Sun et al. (2014) (15) USA White HB Taqman 130 125 17 64 49 30 Garcia-Gonzalez et al. (2015) (34) Spain White HB Taqman 603 675 154 302 147 199 Gonzales-Hormazabal et al. (2020) (16) Chile Other HB Taqman 803 675 154 302 147 199 Gonzales-Hormazabal et al. (2020) (16) Chile Other HB Taqman 871 390 133 461 277 122 Project for Cancer et al. (2008) (17) Japan Asian HB GWAS 1,524 1,396 96 700 728 210 Wu et al. (2009) (18) China Asian PB PCR-RFLP 1,710 995 759 819 132 506 Matsuo et al. (2010) (20) China Asian HB Taqman 708 330 329 <t< td=""><td></td><td>310 0.0884</td></t<>		310 0.0884
Sun et al. (2014) (15) USA White HB Taqman 130 125 17 64 49 30 Garcia-Gonzalez et al. (2015) (34) Spain White HB Taqman 603 675 154 302 147 199 Gonzales-Hormazabal et al. (2020) (16) Chile Other HB Other 307 310 110 162 35 87 The Study Group of Millennium Genome Project for Cancer et al. (2008) (17) Korea Asian HB Taqman 871 390 133 461 277 122 Wu et al. (2009) (18) China Asian PB PCR-RFLP 1,710 995 759 819 132 506 Matsuo et al. (2010) (20) China Asian PB PCR-RFLP 1,710 995 759 819 132 506 Que et al. (2010) (20) China Asian PB PCR-RFLP 1,60 708 330 329 49 273 Que et al. (2010) (20) China Asian HB PCR-RFLP 196 246 <	507 31	0.2692
Garcia-Gonzalez et al. (2015) (34) Spain White HB Taqman 603 675 154 302 147 199 Gonzales-Hormazabal et al. (2020) (16) Chile Other HB Other 307 310 110 162 35 87 The Study Group of Millennium Genome Project for Cancer et al. (2008) (17) Korea Asian HB Taqman 871 390 133 461 277 122 The Study Group of Millennium Genome Project for Cancer et al. (2008) (17) Japan Asian HB GWAS 1,524 1,396 96 700 728 210 Wu et al. (2009) (18) China Asian PB PCR-RFLP 1,710 995 759 819 132 506 Matsuo et al. (2009) (19) Japan Asian HB Taqman 708 708 330 329 49 273 Ou et al. (2010) (20) China Asian HB PCR-RFLP 196 246 85 93 18 132 Lu et al. (2010) (21) China Asian PB PCR-RFLP	123 5	56 0.834
Gonzales-Hormazabal et al. (2020) (16)ChileOtherHBOther3073101101623587The Study Group of Millennium Genome Project for Cancer et al. (2008) (17)KoreaAsianHBTaqman871390133461277122The Study Group of Millennium Genome Project for Cancer et al. (2008) (17)JapanAsianHBGWAS1,5241,39696700728210Wu et al. (2009) (18)ChinaAsianPBPCR-RFLP1,710995759819132506Matsuo et al. (2009) (19)JapanAsianHBTaqman70870833032949273Ou et al. (2010) (20)ChinaAsianHBPCR-RFLP196246859318132Lu et al. (2010) (21)ChinaAsianPBPCR-RFLP1,0231,06954740472605Zeng et al. (2011) (22)ChinaAsianHBPCR-RFLP46054920221642289	63 3	32 0.9264
The Study Group of Millennium Genome Project for Cancer et al. (2008) (17)KoreaAsianHBTaqman871390133461277122The Study Group of Millennium Genome Project for Cancer et al. (2008) (17)JapanAsianHBGWAS1,5241,39696700728210Wu et al. (2009) (18)ChinaAsianPBPCR-RFLP1,710995759819132506Matsuo et al. (2009) (19)JapanAsianHBTaqman70870833032949273Ou et al. (2010) (20)ChinaAsianHBPCR-RFLP196246859318132Lu et al. (2010) (21)ChinaAsianPBPCR-RFLP1,0231,06954740472605Zeng et al. (2011) (22)ChinaAsianHBPCR-RFLP46054920221642289	346 13	0.3495
Project for Cancer et al. (2008) (17) The Study Group of Millennium Genome Project for Canceret al. (2008) (17) Wu et al. (2009) (18) China Asian PB PCR-RFLP 1,710 995 759 819 132 506 Matsuo et al. (2009) (19) Japan Asian HB Taqman 708 708 330 329 49 273 Ou et al. (2010) (20) China Asian HB PCR-RFLP 196 246 85 93 18 132 Lu et al. (2010) (21) China Asian PB PCR-RFLP 1,023 1,069 547 404 72 605 Zeng et al. (2011) (22) China Asian HB PCR-RFLP 460 549 202 216 42 289	156 6	67 0.851
Project for Canceret al. (2008) (17) Wu et al. (2009) (18) China Asian PB PCR-RFLP 1,710 995 759 819 132 506 Matsuo et al. (2009) (19) Japan Asian HB Taqman 708 708 330 329 49 273 Ou et al. (2010) (20) China Asian HB PCR-RFLP 196 246 85 93 18 132 Lu et al. (2010) (21) China Asian PB PCR-RFLP 1,023 1,069 547 404 72 605 Zeng et al. (2011) (22) China Asian HB PCR-RFLP 460 549 202 216 42 289	176 9	92 0.069
Matsuo et al. (2009) (19)JapanAsianHBTaqman70870833032949273Ou et al. (2010) (20)ChinaAsianHBPCR-RFLP196246859318132Lu et al. (2010) (21)ChinaAsianPBPCR-RFLP1,0231,06954740472605Zeng et al. (2011) (22)ChinaAsianHBPCR-RFLP46054920221642289	650 53	536 0.5738
Ou et al. (2010) (20) China Asian HB PCR-RFLP 196 246 85 93 18 132 Lu et al. (2010) (21) China Asian PB PCR-RFLP 1,069 547 404 72 605 Zeng et al. (2011) (22) China Asian HB PCR-RFLP 460 549 202 216 42 289	412 7	77 0.5865
Lu et al. (2010) (21) China Asian PB PCR-RFLP 1,023 1,069 547 404 72 605 Zeng et al. (2011) (22) China Asian HB PCR-RFLP 460 549 202 216 42 289	338 9	97 0.6378
Zeng et al. (2011) (22) China Asian HB PCR-RFLP 460 549 202 216 42 289	96 1	18 0.9243
	387 7	77 0.1664
Song et al. (2011) (22) Korea Asian HP DCP DELD 2 220 1 700 570 1620 1040 414	223 3	37 0.4932
Song et al. (2011) (23) Rolea Asiali 11D FCR-RFLF 5,255 1,700 570 1020 1045 414	818 40	468 0.1305
Li et al. (2012) (24) China Asian PB Other 300 300 124 141 35 168	111 2	21 0.6501
Zhao et al. (2013) (25) China Asian PB Other 717 951 275 342 100 465	401 8	85 0.9127
Ichikawa et al. (2015) (26) Japan Asian HB PCR-RFLP 193 266 24 104 65 52	119 9	95 0.1851
Zhang et al. (2015) (27) China Asian HB Other 475 480 227 207 41 261	183 3	36 0.6177
Mou et al. (2015) (28) China Asian PB Other 198 130 23 126 49 5	34 9	91 0.4257
Turdikulova et al. (2016) (29) Uzbekistan Asian HB PCR-RFLP 268 248 78 190 0 119	109 2	20 0.4721
Qiu et al. (2016) (30) China Asian HB Taqman 1,124 1,192 537 489 98 663	383 14	46 <0.05
Sun et al. (2015) (31) China Asian HB Taqman 702 774 332 309 61 405	297 7	72 0.1052
Cai et al. (2017) (10) China Asian PB PCR-RFLP 485 488 215 225 45 268	173 4	47 <0.05
Sung et al. (2017) (7) China Asian HB GWAS 194 170 24 112 58 54	84 3	32 0.9473
Yan et al. (2019) (32) China Asian HB Taqman 549 592 269 236 44 337	191 6	64 <0.05
Alikhani et al. (2020) (8) Iran Asian HB PCR-RFLP 99 96 62 29 8 63	24 9	9 <0.05
Guan (2020) (33) China HB Asian Other 982 1,964 615 337 30 1,071		49 0.2115

SOC, source of control; HB, hospital-based controls; PB, population-based controls; GWAS, Genome-Wide Association Studies; PCR-RFLP, Polymerase Chain Reaction-restriction fragment length polymorphism; HWE, Hardy-Weinberg equilibrium.



an increased risk of GC (CT+TT vs. CC: OR=1.42, 95% CI: 1.24-1.63; TT vs. CT +CC: OR=1.03, 95% CI: 0.86-1.23; TT vs. CC: OR=1.29, 95% CI: 1.02-1.62; CT vs. CC: OR=1.43, 95% CI: 1.26-1.61; and T vs. C: OR=1.15, 95% CI: 1.03-1.29) (Figure 2). Stratified by ethnicity, PSCA rs2294008 was most significant in white populations (CT+TT vs. CC: OR=1.56, 95% CI: 1.01-1.20; TT vs. CT+CC: OR=1.51, 95% CI: 1.32-1.73; TT vs. CC: OR=1.92, 95% CI: 1.49-2.48; CT vs. CC: OR=1.38, 95% CI: 1.07-1.78; and T vs. C: OR=1.38, 95% CI: 1.22-1.57). From the subgroup analysis of genotyping technology, Genome-Wide Association Studies was very significant in the detection of related cancer susceptibility (CT+TT vs. CC: OR=2.74, 95% CI: 2.18-3.45; TT vs. CT+CC: OR=1.49, 95% CI: 1.30-1.72; TT vs. CC: OR=3.11, 95% CI: 2.43-3.98; CT vs. CC: OR=2.46, 95% CI: 1.94-3.13; and T vs. C: OR=1.59, 95% CI: 1.33-1.91). Furthermore, we found that the PSCA rs2294008 C>T polymorphism was associated with GC anatomical location, Lauren classification, HP infection status, and smoker status, while gender was not significantly associated with PSCA rs2294008 expression.

Sensitivity and heterogeneity analyses

The analysis of the included studies revealed significant heterogeneity (CT+TT vs. CC: *P*<0.00001, I ² ⁼ 87.5%; TT vs. CC +CT: *P*<0.00001, I ² ⁼ 87.5%; TT vs. CC: *P*<0.00001, I ² ⁼ 89.1%; CT vs. CC: *P*<0.00001, I ² ⁼ 81.9%; and T vs. C: *P*<0.00001, I ² ⁼ 91.9%). Sensitivity analyses were repeated, ignoring one study per repetition in order to identify sources of heterogeneity. The results showed

that the main sources of heterogeneity were Mou et al. (28), Turdikulova et al. (29), and Gonzalez-Hormazabal et al. (16). The heterogeneity was significantly reduced after excluding the above three studies (CT+TT vs. CC: P<0.00001, I ² = 80.5%; TT vs. CC +CT: P<0.00001, I ² = 74.9%; TT vs. CC: P<0.00001, I ² = 83.0%; CT vs. CC: P<0.00001, I ² = 72.9%; and T vs. C: P<0.00001, I ² = 74.0%).

Publication bias

We performed statistical analysis on publication bias in the included literature. The result is shown in Figure 3. Begg's funnel plot for the dominant model is symmetrical, and no significant bias is shown, which was confirmed by Egger's test (dominant: P=0.180, recessive: P=0.106, homozygous: P=0.272, heterozygous: P=0.141, and allelic: P=0.640).

Discussion

Prostate stem cell antigen (PSCA) is a protein that binds to the cell surface, and the two are linked by glycosylphosphatidylinositol (GPI). PSCA is found in the human bladder, prostate epithelial cells (35), and stomach, and for the latter, is expressed in the isthmus of the gastric gland. Studies have shown that there may be proliferative precursor cells in the isthmus, and PSCA can act on those cells to negatively affect tumor proliferation (17). Xu et al. (35) detected by Western blotting that the content of PSCA in GC was much lower than that in normal gastric mucosa. With *in vitro* functional experiments, silencing

1.3	~ *	~ 1	
LI	eι	al.	

Variables	No. of studies	Homozygous (TT vs. CC)			Heterozygous (CT vs. CC)		Recessive [TT vs. (CT+CC)]			Dominant [(CT+TT) vs. CC]			Allelic (Comparing T vs. C)			
		OR (95% CI)	P eff	P het	OR (95% CI)	P eff	P het	OR (95% CI)	P eff	P het	OR (95% CI)	P eff	P het	OR (95% CI)	P eff	P het
All	28	1.36 (1.09, 1.69)	0.006	< 0.00001	1.46 (1.31, 1.63)	< 0.001	< 0.00001	1.07 (0.90, 1.27)	0.428	< 0.00001	1.46 (1.29, 1.65)	<0.001	<0.00001	1.17 (1.05, 1.31)	0.004	<0.00001
Ethnicity																
White	7	1.92 (1.49, 2.48)	< 0.001	0.033	1.38 (1.07, 1.78)	0.013	0.009	1.51 (1.32, 1.73)	< 0.001	0.333	1.56 (1.21, 2.01)	0.001	0.004	1.38 (1.22, 1.57)	< 0.001	0.029
Asian	20	1.26 (0.97, 1.64)	0.087	< 0.00001	1.52 (1.35, 1.73)	< 0.001	< 0.00001	0.97 (0.78, 1.20)	0.76	< 0.00001	1.48 (1.28, 1.70)	< 0.001	< 0.00001	1.18 (1.05, 1.31)	0.004	<0.00001
Other	1	0.41 (0.25, 0.68)	< 0.001	/	0.82 (0.57, 1.17)	0.28	/	0.47 (0.30, 0.73)	/	/	0.70 (0.50, 0.98)	/	/	0.37 (0.29, 0.46)	< 0.001	/
Genotyping																
Taqman	12	1.45 (1.03, 2.05)	0.035	< 0.00001	1.40 (1.15, 1.70)	0.001	< 0.00001	1.17 (0.92, 1.50)	0.203	< 0.00001	1.45 (1.17, 1.79)	0.001	< 0.00001	1.26 (1.09, 1.45)	0.002	<0.00001
PCR- RFLP	9	1.30 (1.05, 1.60)	0.016	0.214	1.47 (1.28, 1.69)	< 0.001	0.015	1.07 (0.89, 1.28)	0.475	0.06	1.43 (1.27, 1.61)	< 0.001	0.044	1.21 (1.15, 1.28)	< 0.001	0.618
GWAS	2	3.11 (2.43, 3.98)	< 0.001	0.374	2.46 (1.94, 3.13)	< 0.001	0.443	1.49 (1.30, 1.72)	< 0.0001	0.389	2.74 (2.18, 3.45)	< 0.001	0.457	1.59 (1.33, 1.91)	< 0.001	0.195
Other	5	0.84 (0.37, 1.93)	0.685	< 0.00001	1.26 (0.99, 1.62)	0.064	0.03	0.74 (0.30, 1.83)	0.516	< 0.00001	1.11 (0.76, 1.63)	0.582	< 0.00001	0.78 (0.42, 1.44)	0.421	<0.00001
SOC																
РВ	10	1.36 (1.01, 1.84)	0.042	< 0.00001	1.37 (1.19, 1.58)	< 0.001	0.012	1.06 (0.75, 1.50)	0.737	<0.00001	1.39 (1.18, 1.64)	< 0.001	< 0.00001	1.15 (0.96, 1.38)	0.118	<0.00001
HB	18	1.37 (1.01, 1.85)	0.042	<0.00001	1.52 (1.30, 1.78)	<0.001	<0.00001	1.08 (0.88, 1.31)	0.469	<0.00001	1.52 (1.27, 1.81)	< 0.001	<0.00001	1.19 (1.03, 1.37)	0.019	<0.00001
Subgroup by l	location															
Cardia	6	1.13 (0.75, 1.70)	0.572	0.135	0.95 (0.65, 1.39)	0.778	0.039	1.17 (0.90, 1.51)	0.232	0.496	0.99 (0.68, 1.44)	0.969	0.031	1.05 (0.85, 1.30)	0.629	0.095
Non- cardia	6	1.71 (1.38, 2.12)	<0.0001	0.493	1.27 (1.03, 1.56)	0.023	0.228	1.53 (1.28, 1.83)	< 0.0001	0.501	1.40 (1.18, 1.65)	< 0.0001	0.36	1.33 (1.19, 1.48)	< 0.0001	0.362
Subgroup by I	histology															
Intestinal	12	1.39 (1.01, 1.91)	0.046	< 0.00001	1.34 (1.11, 1.62)	0.002	< 0.00001	1.17 (0.95, 1.44)	0.13	< 0.00001	1.37 (1.10, 1.70)	0.004	<0.00001	1.21 (1.05, 1.41)	0.01	<0.00001
Diffuse	12	2.44 (1.63, 3.65	< 0.0001	< 0.00001	1.71 (1.26, 2.33)	0.001	< 0.00001	1.67 (1.35, 2.06)	< 0.0001	0.001	1.91 (1.38, 2.66)	< 0.0001	< 0.00001	1.52 (1.29, 1.79)	< 0.0001	<0.00001
Helicobacter f	pylori															
Positive	3	1.20 (0.83, 3.14)	0.966	<0.00001	1.17 (0.80, 1.71)	0.426	0.007	1.26 (0.71, 2.35)	0.84	<0.00001	1.20 (0.70, 2.06)	0.507	<0.00001	1.10 (0.69, 1.76)	0.689	<0.00001
Negative	3	1.08 (0.39, 2.96)	0.884	< 0.00001	1.14 (0.66, 1.98)	0.762	0.041	1.08 (0.51, 2.30)	0.839	0.004	1.01 (0.55, 1.82)	0.99	0.002	1.03 (0.62, 1.72)	0.913	<0.00001
Sex																
Male	6	1.02 (0.37, 2.85)	0.97	< 0.00001	1.23 (1.03, 1.46)	0.021	0.060	0.96 (0.44, 2.12)	0.925	0.001	/	/	/	1.02 (0.65, 1.61)	0.915	<0.00001
Female	6	0.58 (0.18, 1.84)	0.353	0.015	1.19 (0.95, 1.49)	0.127	0.220	0.59 (0.18, 1.95)	0.391	0.007	1.13 (0.87, 1.47)	0.344	0.078	0.88 (0.56, 1.38)	0.587	0.047
Smoker																
Never	6	1.37 (0.36, 5.25)	0.647	< 0.00001	1.35 (1.08, 1.69)	0.009	0.033	1.01 (0.41, 2.49)	0.991	0.001	1.50 (0.67, 3.38)	0.323	< 0.00001	1.93 (1.26, 2.95)	0.002	0.020
Ever	6	1.21 (0.41, 3.58)	0.737	< 0.00001	1.16 (0.97, 1.38)	0.102	0.169	1.16 (0.50, 2.66)	0.734	< 0.00001	1.18 (0.93, 1.50)	0.161	0.012	1.14 (0.69, 1.88)	0.621	<0.00001

TABLE 2 Meta-analysis of prostate stem cell antigen (PSCA) rs2294008 association with gastric cancer subgroups.

No., number; vs., versus; OR, odds ratio; CI, confidential interval; PEff, p-value of pooled effect; PHet, p-value of heterogeneity test.

PSCA could promote the proliferation of GC cells, and overexpression would lead to inhibition. In the previous metaanalysis (6), it was confirmed that the PSCA rs2294008 C>T polymorphism level was significantly raised in GC. In this updated meta-analysis, with a total of 28 studies containing 18,495 patients and 19,219 healthy controls, we confirmed that PSCA rs2294008 was clearly associated with GC susceptibility, particularly evident in dominant models.



Sakamoto et al. (17) first found that rs2294008 in Asian populations regulates the transcriptional activity upstream of PSCA and has been shown to act on the proliferation process of gastric cancer. Subsequently, Sala et al. (12) also found that PSCA rs2294008 SNP in white populations has the same risk genotype. Our meta-analysis found that in white and Asian

populations TT genotypes are strongly associated with the former whereas TC genotypes are associated with cancer risk in Asians. The difference in association between the ethnicities indicates that genetic information can significantly affect SNPs. Whether different genotypes are the main factors affecting the differences in the susceptibility to gastric cancer among ethnic



groups needs to be evaluated further. Gonzalez-Hormazabal et al. (16) found for the first time that PSCA rs2294008 also increased the risk of cancer in Chilean populations, which indicated that PSCA rs2294008 could be seen as a biomarker to estimate the genetic risk of gastric cancer beyond Asian and white populations.

As genotyping techniques continue to upgrade, whether the accuracy of various techniques causes bias is also an issue to be discussed, and the previous five meta-analyses have not analyzed them. Therefore, we have collected six techniques, namely, Taqman, PCR-RFLP, Genome-Wide Association Studies, MassARRAY, DHPLC, and Sequenom, among which 12 studies used Taqman, nine studies used PCR-RFLP, and two studies used Genome-Wide Association Studies. Classified as "Other," this meta-analysis found statistical significance for all five genotype models. In addition, the correlation between PSCA rs2294008 C>T and GC has been confirmed via Taqman, PCR-RFLP, and Genome-Wide Association Studies, among which GWAS showed a very significant correlation. However, in-depth studies have found that a single SNP usually shows only moderately on the GWAS platform effect. A single SNP usually only has marginal effects, ignoring epistatic effects between SNPs, which can significantly contribute to disease susceptibility (18). Taqman has the characteristics of high precision and low cost in the study of single SNP and large sample populations (36). Therefore, we recommend genotyping with GWAS when performing susceptibility analysis on SNP pools and Taqman genotyping on individual SNPs.

Since PSCA is expressed in the gastric gland isthmus, anatomical factors may influence the location of GC. In this meta-analysis, the effect of PSCA rs2294008 on non-cardia gastric cancer was significantly higher than that of cardia gastric cancer, which was consistent with the results of previous studies (32, 37). Similarly, the Lauren classification analysis showed that the disease susceptibility of the diffuse type was higher than that of the intestinal type. In addition, it was found that gender was not correlated with PSCA rs2294008 in the gender analysis, which is opposite to the results of Qiu et al. (30). Considering that the included studies are basically from Asia, a larger gender subgroup analysis is required to validate this finding. Smoking is a wellestablished risk factor of GC, compared with non-drinkers and non-smokers, alcoholics and smokers have a two-fold danger of gastric cancer (38). However, the study found that in all models, non-smokers are more susceptible than smokers, and this difference needs careful analysis.

Previous researchers have reported that a group with *H. pylori* infection in the same PSCA model may have a greater GC susceptibility than HP-negative people (10), Tanikawa et al. (39) found that the growth-promoting effect of the PSCA rs2294008 T gene may increase the risk of HP-induced GC, possibly because the PSCA protein encoded by the T gene has a 9-amino acid fragment attached to the N-terminus, which is longer than the synthetic protein of the C gene, increasing the risk of cancer by facilitating epithelial cell proliferation (40). A recent

study showed that HP infection had a stronger effect on PSCA rs2294008 T carriers, whose PSCA expression was significantly suppressed compared with HP-negative normal (41). These studies support our study that the T gene susceptibility was higher in HP-positive gastric cancer patients than that of the C gene, and the susceptibility of HP-positive patients is higher than that of HP-negative patients in all models. We speculate that HP interacts with PSCA to increase the risk of cancer. However, there are too many susceptibility factors for HP, and the effect of PSCA on such factors needs further study.

We found in the sensitivity analysis that the heterogeneity was significantly reduced after removing the three studies by Mou et al., Turdikulova et al., and Gonzalez-Hormazabal et al. By contrast, Mou et al. confirmed that PSCA rs2294008 was not associated with GC risk, contrary to most results. The study by Turdikulova et al., conducted primarily in Uzbekistan, found that only the CT genotype was associated with significant cancer risk, whereas Asian risk models were susceptible to both TT and CT genotypes. The study by Gonzalez-Hormazabal et al. showed that gastric cancer patients in Chile were not statistically significant in the stealth model, and in a study focusing on Brazil, PSCA rs2976392 was significantly associated with GC risk, we speculate that gastric cancer susceptibility in Latin-American populations may be related to rs2976392, not rs2976392 and rs2294008, which also needs to be confirmed by controlled studies in this population.

In this meta-analysis, we analyzed the association between PSCA rs2294008 and gastric cancer and also analyzed the factors that may influence the association, such as ethnicity, Lauren classification, anatomical site, and gender, and the results were consistent with previous meta-analyses (6, 42). However, the previous analysis did not evaluate the susceptibility factors of gastric cancer, making the evidence of rs2294008 as biomarkers insufficient, while HP infection and smoker status remain key factors in predicting gastric cancer. Therefore, we performed the first statistical analysis of the role of both factors in rs2294008 and gastric cancer, and the results were encouraging. HP infection and rs2294008 correlation was higher than without HP infection, and this new finding may complement the influence of HP in gastric cancer biology and further improve the evidence for rs2294008 as a gastric cancer biomarker.

Conclusion

In conclusion, PSCA rs2294008 C>T can significantly increase susceptibility to GC, especially in Asian and white populations, and non-cardia gastric cancer, diffuse gastric cancer, and HP infection. However, the result that smoking does not increase susceptibility to gastric cancer seems abnormal. Due to the limited number of samples, further prospective studies involving smoking with a more extensive sample size are needed to clarify.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

Ethics statement

Ethical review and approval were not required for this study according to local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the relevant individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

HL performed the data analysis and literature writing; the SS searched all relevant literature; DW contributed to the data analysis; and QZ contributed to the research process. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by a grant from the Changzhi Medical College Academic Leader Program. (KS202003)

References

1. Kole C, Charalampakis N, Tsakatikas S, Kouris N-L, Papaxoinis G, Karamouzis MV, et al. Immunotherapy for gastric cancer: a 2021 update. *Immunotherapy* (2022) 14(1):41-64. doi: 10.2217/imt-2021-0103

2. Zhang X, Hu Q, Chen Y, Li M, Yin H, Zhou C, et al. PSCA rs1045531 polymorphism and the risk of prostate cancer in a Chinese population undergoing prostate biopsy. *Technol Cancer Res Treat* (2017) 16(6):1168–72. doi: 10.1177/1533034617740264

3. Wang M, Wang X, Ma Y, Ma X, Dai Z, Lv Y, et al. PSCA rs2294008 c < T polymorphism contributes to gastric and bladder cancer risk. *TCRM* (2015) 11:237. doi: 10.2147/TCRM.S77089

4. Wang M, Wang XJ, Ma YF, Ma XB, Dai ZM, Lv Y, et al. Single-nucleotide polymorphisms in *PSCA* and the risk of breast cancer in a Chinese population. *Oncotarget* (2016) 7(19):27665–75. doi: 10.18632/oncotarget.8491

5. Xu L, Qiu H, Yuan S, Chen Y, Zhou Z, Chen Y. Downregulation of PSCA promotes gastric cancer proliferation and is related to poor prognosis. *J Cancer* (2020) 11(9):2708–15. doi: 10.7150/jca.33575

6. Qin Z, Tang J, Li X, Yu Y, Zhang C, Han P, et al. Association between PSCA gene polymorphisms and the risk of cancer: an updated meta-analysis and trial sequential analysis. *Oncotarget* (2017) 8(31):51766-78. doi: 10.18632/oncotarget.17011

7. Sung H, Hu N, Yang HH, Giffen CA, Zhu B, Song L, et al. Association of high-evidence gastric cancer susceptibility loci and somatic gene expression levels with survival. *Carcinogenesis* (2017) 38(11):1119–28. doi: 10.1093/carcin/bgx090

8. Alikhani R, Taravati A, Hashemi-Soteh MB. Association of MUC1 5640G>A and PSCA 5057C>T polymorphisms with the risk of gastric cancer in northern iran. *BMC Med Genet* (2020) 21(1):148. doi: 10.1186/s12881-020-01085-z

Acknowledgments

We thank Changzhi Medical College for supporting this research.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/ fgstr.2022.944525/full#supplementary-material

9. Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet (2020) 396(10251):635-48. doi: 10.1016/S0140-6736(20)31288-5

10. Cai M, Dai S, Chen W, Xia C, Lu L, Dai S, et al. Environmental factors, seven GWAS-identified susceptibility loci, and risk of gastric cancer and its precursors in a Chinese population. *Cancer Med* (2017) 6(3):708–20. doi: 10.1002/cam4.1038

11. Lochhead P, Frank B, Hold GL, Rabkin CS, Ng MTH, Vaughan TL, et al. Genetic variation in the prostate stem cell antigen gene and upper gastrointestinal cancer in white individuals. *Gastroenterology* (2011) 140(2):435–41. doi: 10.1053/j.gastro.2010.11.001

12. Sala N, Muñoz X, Travier N, Agudo A, Duell EJ, Moreno V, et al. Prostate stem-cell antigen gene is associated with diffuse and intestinal gastric cancer in caucasians: Results from the EPIC-EURGAST study. *Int J Cancer* (2012) 130 (10):2417–27. doi: 10.1002/ijc.26243

13. Rizzato C, Kato I, Plummer M, Muñoz N, Canzian F. Genetic variation in PSCA and risk of gastric advanced preneoplastic lesions and cancer in relation to helicobacter pylori infection. *PloS One* (2013) 8(9):e73100. doi: 10.1371/journal.pone.0073100

14. Kupcinskas J, Wex T, Link A, Bartuseviciute R, Dedelaite M, Kevalaite G, et al. PSCA and MUC1 gene polymorphisms are linked with gastric cancer and premalignant gastric conditions. *Anticancer Res* (2014) 34:9.

15. Sun Y, Gu J, Ajani JA, Chang DW, Wu X, Stroehlein JR. Genetic and intermediate phenotypic susceptibility markers of gastric cancer in Hispanic americans: A case-control study: Gastric cancer biomarkers in hispanics. *Cancer* (2014) 120(19):3040–8. doi: 10.1002/cncr.28792

16. Gonzalez-Hormazabal P, Retamales-Ortega R, Musleh M, Bustamante M, Stambuk J, Pisano R, et al. Polymorphisms PSCA rs2294008, IL-4 rs2243250 and

MUC1 rs4072037 are associated with gastric cancer in a high risk population. *Mol Biol Rep* (2020) 47(11):9239-43. doi: 10.1007/s11033-020-05943-0

17. The Study Group of Millennium Genome Project for Cancer. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. *Nat Genet* (2008) 40(6):730–40. doi: 10.1038/ng.152

18. Wu MC, Kraft P, Epstein MP, Taylor DM, Chanock SJ, Hunter DJ, et al. Powerful SNP-set analysis for case-control genome-wide association studies. *Am J Hum Genet* (2010) 86(6):929–42. doi: 10.1016/j.ajhg.2010.05.002

19. Matsuo K, Tajima K, Suzuki T, Kawase T, Watanabe M, Shitara K, et al. Association of prostate stem cell antigen gene polymorphisms with the risk of stomach cancer in japanese. *Int J Cancer* (2009) 125(8):1961–4. doi: 10.1002/ ijc.24519

20. Ou J, Li K, Ren H, Bai H, Zeng D, Zhang C. Association and haplotype analysis of prostate stem cell antigen with gastric cancer in tibetans. *DNA Cell Biol* (2010) 29(6):319–23. doi: 10.1089/dna.2009.0960

21. Lu Y, Chen J, Ding Y, Jin G, Wu J, Huang H, et al. Genetic variation of PSCA gene is associated with the risk of both diffuse- and intestinal-type gastric cancer in a Chinese population. *Int J Cancer* (2010) 127(9):2183–9. doi: 10.1002/ijc.25228

22. Zeng Z, Wu X, Chen F, Yu J, Xue L, Hao Y, et al. Polymorphisms in prostate stem cell antigen gene rs2294008 increase gastric cancer risk in Chinese. *Mol Carcinog* (2011) 50(5):353–8. doi: 10.1002/mc.20718

23. Song H-R, Kim HN, Piao JM, Kweon SS, Choi JS, Bae WK, et al. Association of a common genetic variant in prostate stem-cell antigen with gastric cancer susceptibility in a Korean population. *Mol Carcinog* (2011) 50(11):871–5. doi: 10.1002/mc.20796

24. Li F, Zhong M-Z, Li J-H, Liu W, Li B. Case-control study of single nucleotide polymorphisms of PSCA and MUC1 genes with gastric cancer in a chinese. *Asian Pacif J Cancer Prev* (2012) 13(6):2593–6. doi: 10.7314/APJCP.2012.13.6.2593

25. Zhao J, Geng P, Li Z, Cui S, Zhao J, Wang L, et al. Prostate stem cell antigen rs2294008 polymorphism differentially contributes to helicobacter pylori-negative gastric cancer among various populations in china. *Mol Clin Oncol* (2013) 1 (3):493–8. doi: 10.3892/mco.2013.70

26. Ichikawa H, Sugimoto M, Uotani T, Sahara S, Yamade M, Iwaizumi M, et al. Influence of prostate stem cell antigen gene polymorphisms on susceptibility to *Helicobacter pylori* -associated diseases: A case-control study. *Helicobacter* (2015) 20(2):106–13. doi: 10.1111/hel.12183

27. Zhang W, Liang P, Wang W, Dai P, Wang Q, Yan W, et al. The influence of PSCA gene variation on its expression and gastric adenocarcinoma susceptibility in the Northwest Chinese population. *IJMS* (2015) 16(12):11648–58. doi: 10.3390/ ijms160511648

28. Mou X, Li T, Wang J, Ali Z, Zhang Y, Chen Z, et al. Genetic variation of BCL2 (rs2279115), NEIL2 (rs804270), LTA (rs909253), PSCA (rs2294008) and PLCE1 (rs3765524, rs10509670) genes and their correlation to gastric cancer risk based on universal tagged arrays and Fe₃O₄ magnetic nanoparticles. J BioMed Nanotechnol (2015) 11(11):2057–66. doi: 10.1166/jbn.2015.2113

29. Turdikulova S, Dalimova D, Abdurakhimov A, Adilov B, Navruzov S, Yusupbekov A, et al. Association of rs2294008 and rs9297976 polymorphisms in

PSCA gene with gastric cancer susceptibility in uzbekistan. *cajgh* (2016) 5(1):227. doi: 10.5195/cajgh.2016.227

30. Qiu L-X, Cheng L, He J, Zhou ZR, Wang MY, Zhou F, et al. *PSCA* polymorphisms and gastric cancer susceptibility in an eastern Chinese population. *Oncotarget* (2016) 7(8):9420-8. doi: 10.18632/oncotarget.7137

31. Sun H, Wu X, Wu F, Li Y, Yu Z, Chen X, et al. Associations of genetic variants in the PSCA, MUC1 and PLCE1 genes with stomach cancer susceptibility in a Chinese population. *PloS One* (2015) 10(2):e0117576. doi: 10.1371/journal.pone.0117576

32. Yan K, Wu K, Lin C, Jie Z. Impact of *PSCA* gene polymorphisms in modulating gastric cancer risk in the Chinese population. *Biosci Rep* (2019) 39(9): BSR20181025. doi: 10.1042/BSR20181025

33. Guan F. Risk of gastric ulcer contributed by genetic polymorphisms of PSCA_ a case-control study based on Chinese han population. *Gene* (2020) 757:6. doi: 10.1016/j.gene.2020.144941

34. García-González MA, Bujanda L, Quintero E, Santolaria S, Benito R, Strunk M, et al. Association of PSCA rs2294008 gene variants with poor prognosis and increased susceptibility to gastric cancer and decreased risk of duodenal ulcer disease: Association of PSCA rs2294008 gene polymorphism with gastric cancer susceptibility and prognosis. *Int J Cancer* (2015) 137(6):1362–73. doi: 10.1002/ ijc.29500

35. Classon BJ, Coverdale L. Mouse stem cell antigen sca-2 is a member of the ly-6 family of cell surface proteins.. *Proc Natl Acad Sci USA* (1994) 91(12):5296–300. doi: 10.1073/pnas.91.12.5296

36. Shen G-Q, Abdullah KG, Wang QK. The TaqMan method for SNP genotyping. In: Komar AA, Totowa ED, editors. *Single nucleotide polymorphisms*, vol. 578. NJ: Humana Press (2009). p. 293–306. doi: 10.1007/978-1-60327-411-1_19

37. Gu Y, Dai QS, Hua RX, Zhang B, Zhu JH, Huang JW, et al. PSCA s2294008 C>T and rs2976392 G>A polymorphisms contribute to cancer susceptibility: evidence from published studies. *Genes Cancer* (2015) 6(5-6):254-64. doi: 10.18632/genesandcancer.63

38. Dong J, Thrift AP. Alcohol, smoking and risk of oesophago-gastric cancer. Best Pract Res Clin Gastroenterol (2017) 31(5):509-17. doi: 10.1016/j.bpg.2017.09.002

39. Tanikawa C, Urabe Y, Matsuo K, Kubo M, Takahashi A, Ito H, et al. A genome-wide association study identifies two susceptibility loci for duodenal ulcer in the Japanese population. *Nat Genet* (2012) 44(4):430–4. doi: 10.1038/ng.1109

40. Usui Y, Matsuo K, Oze I, Ugai T, Koyanagi Y, Maeda Y, et al. Impact of *PSCA* polymorphisms on the risk of duodenal ulcer. *J Epidemiol* (2021) 31(1):12–20. doi: 10.2188/jea.JE20190184

41. Toyoshima O, Tanikawa C, Yamamoto R, Watanabe H, Yamashita H, Sakitani K, et al. Decrease in *PSCA* expression caused by *Helicobacter pylori* infection may promote progression to severe gastritis. *Oncotarget* (2018) 9 (3):3936–45. doi: 10.18632/oncotarget.23278

42. Geng P, Li J, Wang N, Ou J, Xie G, Liu C, et al. PSCA rs2294008 polymorphism with increased risk of cancer. *PloS One* (2015) 10(8):e0136269. doi: 10.1371/journal.pone.0136269